<p>Sensus Healthcare, Inc.（納斯達克代碼：SRTS - 獲取免費報告）董事 Eric Sachetta 於 11 月 21 日星期五收購了 7,000 股 Sensus Healthcare 股票。該股票的平均購買價格為每股 3.93 美元，總價值為 27,510.00 美元。交易完成後，該董事直接持有公司 140,113 股股票，價值 550,644.09 美元。這代表其持股增加了 5.26%。該交易已在向 SEC 提交的文件中披露，您可以通過此超鏈接訪問。</p>
<p>Eric Sachetta 最近還進行了以下交易：</p>
<ul>
<li>在 11 月 13 日星期四，Eric Sachetta 購買了 2,500 股 Sensus Healthcare 股票。該股票的平均價格為每股 4.50 美元，總交易額為 11,250.00 美元。</li>
</ul>
<p>獲取 <strong>Sensus Healthcare</strong> 的提醒：</p>
<h2>Sensus Healthcare 股價上漲 1.9%</h2>
<p>在星期五的交易中，SRTS 股票上漲了 0.07 美元，達到了 4.00 美元。該公司的股票交易量為 49,595 股，而其平均交易量為 167,241 股。該公司的 50 日移動平均線為 3.45 美元，200 日移動平均線為 4.06 美元。Sensus Healthcare, Inc.的 52 周最低價為 3.03 美元，52 周最高價為 9.33 美元。該公司的市值為 6577 萬美元，市盈率為-66.65，貝塔值為 1.38。</p>
<p>Sensus Healthcare（納斯達克代碼：SRTS - 獲取免費報告）最近於 11 月 6 日星期四發佈了其財報。該公司報告本季度每股收益（EPS）為-0.06 美元，超出分析師一致預期的-0.12 美元，超出幅度為 0.06 美元。Sensus Healthcare 的股本回報率為-1.58%，淨利潤率為-2.26%。該公司本季度的收入為 688 萬美元，而分析師預期為 631 萬美元。整體來看，研究分析師預測 Sensus Healthcare, Inc.在當前年度將發佈 0.32 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Vise Technologies Inc.在第二季度購買了 Sensus Healthcare 的新股份，價值約 52,000 美元。IFP Advisors Inc.在第一季度將其在 Sensus Healthcare 的持股增加了 37.2%。IFP Advisors Inc.現在擁有 18,800 股該公司的股票，價值 89,000 美元，此前在上個季度又購買了 5,100 股。Trexquant Investment LP 在第一季度購買了 Sensus Healthcare 的新頭寸，價值 93,000 美元。American Century Companies Inc.在第一季度將其在 Sensus Healthcare 的持股增加了 12.7%。American Century Companies Inc.現在擁有 22,440 股該公司的股票，價值 106,000 美元，此前在上個季度又購買了 2,520 股。最後，Chapin Davis Inc.在第二季度將其在 Sensus Healthcare 的持股增加了 66.7%。Chapin Davis Inc.現在擁有 25,000 股該公司的股票，價值 118,000 美元，此前在上個季度又購買了 10,000 股。目前，25.30% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>一些股票分析師對該股票發表了看法。Lake Street Capital 將 Sensus Healthcare 的目標價從 13.00 美元下調至 6.00 美元，並在 8 月 8 日的研究報告中給予該公司 “買入” 評級。Wall Street Zen 在 11 月 8 日的報告中將 Sensus Healthcare 的評級從 “賣出” 上調至 “持有”。Zacks Research 在 10 月 22 日的研究報告中將 Sensus Healthcare 的評級從 “強烈賣出” 上調至 “持有”。HC Wainwright 在 8 月 12 日的研究報告中將 Sensus Healthcare 的目標價從 12.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 Sensus Healthcare 的 “賣出（d）” 評級。三位分析師對該股票給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價為 8.00 美元。</p>
<p><strong>閲讀我們最新的 SRTS 股票分析</strong></p>
<h2>關於 Sensus Healthcare</h2>
<p>（獲取免費報告）</p>
<p>Sensus Healthcare, Inc.是一家醫療設備公司，向全球醫療服務提供商製造和銷售放射治療設備。該公司在其治療設備組合中使用表面放射治療，這是一種低能量 X 射線技術。它提供 SRT-100，這是一種光子 X 射線低能量表面放射治療系統，為患者提供了一種替代手術的選擇，用於治療非黑色素瘤皮膚癌，包括基底細胞癌和鱗狀細胞癌，以及其他皮膚病，如瘢痕疙瘩；以及 SRT-100 Vision，提供給用户一個針對表面放射治療量身定製的治療計劃應用程序，集成了嵌入式高頻超聲成像模塊、腫瘤體積分析、射束邊緣規劃和劑量參數。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而非 Sensus Healthcare</li>
<li>技術指標如何幫助您找到被超賣的股票</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區間嗎？</li>
<li>三隻國防股票將受益於軍事支出的增加</li>
<li>Cloudflare 剛剛打破了互聯網，但它仍然是一個炙手可熱的買入</li>
<li>恒生指數是什麼？</li>
<li>Anthropic 剛剛成為人工智能的熱門項目——得到微軟和 NVIDIA 的支持</li>
</ul>
<p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Sensus Healthcare 嗎？</h2>
<p>在您考慮 Sensus Healthcare 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Sensus Healthcare 並不在名單上。</p>
<p>雖然 Sensus Healthcare 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Sensus醫療保健

<p>Sensus Healthcare 董事 Eric Sachetta 以每股 3.93 美元的價格購買了 7,000 股，總計 27,510 美元，增持幅度為 5.26%。該交易已在 SEC 備案中披露。Sensus Healthcare 的股票上漲了 1.9%，達到 4.00 美元，市值為 6577 萬美元。分析師的評級意見不一，普遍維持 “持有” 評級，平均目標價為 8.00 美元。最近的財報超出預期，報告每股收益為（0.06 美元），而預測為（0.12 美元）。機構投資者已調整在公司的持股比例</p>

<p>Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta acquired 7,000 shares of Sensus Healthcare stock in a transaction on Friday, November 21st. The stock was purchased at an average cost of $3.93 per share, with a total value of $27,510.00. Following the completion of the transaction, the director directly owned 140,113 shares in the company, valued at $550,644.09. This represents a 5.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Sensus Healthcare, Inc.（納斯達克代碼：SRTS - 獲取免費報告）董事 Eric Sachetta 於 11 月 21 日星期五收購了 7,000 股 Sensus Healthcare 股票。該股票的平均購買價格為每股 3.93 美元，總價值為 27,510.00 美元。交易完成後，該董事直接持有公司 140,113 股股票，價值 550,644.09 美元。這代表其持股增加了 5.26%。該交易已在向 SEC 提交的文件中披露，您可以通過此超鏈接訪問。</p>
</div><p>Eric Sachetta also recently made the following trade(s):</p>
<div class="lb-trans"><p>Eric Sachetta 最近還進行了以下交易：</p>
</div><ul>
<li>On Thursday, November 13th, Eric Sachetta bought 2,500 shares of Sensus Healthcare stock. The stock was acquired at an average price of $4.50 per share, for a total transaction of $11,250.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 13 日星期四，Eric Sachetta 購買了 2,500 股 Sensus Healthcare 股票。該股票的平均價格為每股 4.50 美元，總交易額為 11,250.00 美元。</li>
</ul>
</div><p>Get <strong>Sensus Healthcare</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sensus Healthcare</strong> 的提醒：</p>
</div><h2>Sensus Healthcare Trading Up 1.9%</h2>
<div class="lb-trans"><h2>Sensus Healthcare 股價上漲 1.9%</h2>
</div><p>Shares of SRTS stock traded up $0.07 during trading on Friday, hitting $4.00. The company's stock had a trading volume of 49,595 shares, compared to its average volume of 167,241. The business has a fifty day moving average of $3.45 and a 200-day moving average of $4.06. Sensus Healthcare, Inc. has a 52 week low of $3.03 and a 52 week high of $9.33. The company has a market cap of $65.77 million, a PE ratio of -66.65 and a beta of 1.38.</p>
<div class="lb-trans"><p>在星期五的交易中，SRTS 股票上漲了 0.07 美元，達到了 4.00 美元。該公司的股票交易量為 49,595 股，而其平均交易量為 167,241 股。該公司的 50 日移動平均線為 3.45 美元，200 日移動平均線為 4.06 美元。Sensus Healthcare, Inc.的 52 周最低價為 3.03 美元，52 周最高價為 9.33 美元。該公司的市值為 6577 萬美元，市盈率為-66.65，貝塔值為 1.38。</p>
</div><p>Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The company had revenue of $6.88 million for the quarter, compared to analysts' expectations of $6.31 million. As a group, research analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.</p>
<div class="lb-trans"><p>Sensus Healthcare（納斯達克代碼：SRTS - 獲取免費報告）最近於 11 月 6 日星期四發佈了其財報。該公司報告本季度每股收益（EPS）為-0.06 美元，超出分析師一致預期的-0.12 美元，超出幅度為 0.06 美元。Sensus Healthcare 的股本回報率為-1.58%，淨利潤率為-2.26%。該公司本季度的收入為 688 萬美元，而分析師預期為 631 萬美元。整體來看，研究分析師預測 Sensus Healthcare, Inc.在當前年度將發佈 0.32 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vise Technologies Inc. purchased a new stake in Sensus Healthcare in the second quarter worth approximately $52,000. IFP Advisors Inc grew its holdings in shares of Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock valued at $89,000 after purchasing an additional 5,100 shares during the last quarter. Trexquant Investment LP purchased a new position in Sensus Healthcare in the 1st quarter worth $93,000. American Century Companies Inc. lifted its stake in Sensus Healthcare by 12.7% in the first quarter. American Century Companies Inc. now owns 22,440 shares of the company's stock worth $106,000 after purchasing an additional 2,520 shares during the last quarter. Finally, Chapin Davis Inc. lifted its stake in Sensus Healthcare by 66.7% in the second quarter. Chapin Davis Inc. now owns 25,000 shares of the company's stock worth $118,000 after purchasing an additional 10,000 shares during the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Vise Technologies Inc.在第二季度購買了 Sensus Healthcare 的新股份，價值約 52,000 美元。IFP Advisors Inc.在第一季度將其在 Sensus Healthcare 的持股增加了 37.2%。IFP Advisors Inc.現在擁有 18,800 股該公司的股票，價值 89,000 美元，此前在上個季度又購買了 5,100 股。Trexquant Investment LP 在第一季度購買了 Sensus Healthcare 的新頭寸，價值 93,000 美元。American Century Companies Inc.在第一季度將其在 Sensus Healthcare 的持股增加了 12.7%。American Century Companies Inc.現在擁有 22,440 股該公司的股票，價值 106,000 美元，此前在上個季度又購買了 2,520 股。最後，Chapin Davis Inc.在第二季度將其在 Sensus Healthcare 的持股增加了 66.7%。Chapin Davis Inc.現在擁有 25,000 股該公司的股票，價值 118,000 美元，此前在上個季度又購買了 10,000 股。目前，25.30% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of equities analysts have weighed in on the stock. Lake Street Capital cut their target price on shares of Sensus Healthcare from $13.00 to $6.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, August 8th. Wall Street Zen raised shares of Sensus Healthcare from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Zacks Research upgraded shares of Sensus Healthcare from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, October 22nd. HC Wainwright dropped their target price on Sensus Healthcare from $12.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, August 12th. Finally, Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Sensus Healthcare in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $8.00.</p>
<div class="lb-trans"><p>一些股票分析師對該股票發表了看法。Lake Street Capital 將 Sensus Healthcare 的目標價從 13.00 美元下調至 6.00 美元，並在 8 月 8 日的研究報告中給予該公司 “買入” 評級。Wall Street Zen 在 11 月 8 日的報告中將 Sensus Healthcare 的評級從 “賣出” 上調至 “持有”。Zacks Research 在 10 月 22 日的研究報告中將 Sensus Healthcare 的評級從 “強烈賣出” 上調至 “持有”。HC Wainwright 在 8 月 12 日的研究報告中將 Sensus Healthcare 的目標價從 12.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 Sensus Healthcare 的 “賣出（d）” 評級。三位分析師對該股票給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價為 8.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on SRTS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 SRTS 股票分析</strong></p>
</div><h2>About Sensus Healthcare</h2>
<div class="lb-trans"><h2>關於 Sensus Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.</p>
<div class="lb-trans"><p>Sensus Healthcare, Inc.是一家醫療設備公司，向全球醫療服務提供商製造和銷售放射治療設備。該公司在其治療設備組合中使用表面放射治療，這是一種低能量 X 射線技術。它提供 SRT-100，這是一種光子 X 射線低能量表面放射治療系統，為患者提供了一種替代手術的選擇，用於治療非黑色素瘤皮膚癌，包括基底細胞癌和鱗狀細胞癌，以及其他皮膚病，如瘢痕疙瘩；以及 SRT-100 Vision，提供給用户一個針對表面放射治療量身定製的治療計劃應用程序，集成了嵌入式高頻超聲成像模塊、腫瘤體積分析、射束邊緣規劃和劑量參數。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Sensus Healthcare</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>Cloudflare Just Broke the Internet, But It’s Still a Red-Hot Buy</li>
<li>What is the Hang Seng index?</li>
<li>Anthropic Just Became AI’s Hottest Ticket—Backed by Microsoft and NVIDIA</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Sensus Healthcare</li>
<li>技術指標如何幫助您找到被超賣的股票</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區間嗎？</li>
<li>三隻國防股票將受益於軍事支出的增加</li>
<li>Cloudflare 剛剛打破了互聯網，但它仍然是一個炙手可熱的買入</li>
<li>恒生指數是什麼？</li>
<li>Anthropic 剛剛成為人工智能的熱門項目——得到微軟和 NVIDIA 的支持</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sensus Healthcare Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Sensus Healthcare 嗎？</h2>
</div><p>Before you consider Sensus Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Sensus Healthcare 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Sensus Healthcare 並不在名單上。</p>
</div><p>While Sensus Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sensus Healthcare 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內幕交易：Sensus 醫療保健（NASDAQ:SRTS）的一位董事購買了 7,000 股股票